Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Quotient Limited Ord (QTNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,700
  • Shares Outstanding, K 54,120
  • Annual Sales, $ 24,730 K
  • Annual Income, $ -82,340 K
  • 36-Month Beta 0.18
  • Price/Sales 15.78
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +37.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.99 +4.86%
on 08/15/18
8.44 -13.15%
on 07/20/18
-0.25 (-3.30%)
since 07/16/18
3-Month
4.60 +59.35%
on 05/17/18
9.02 -18.74%
on 06/20/18
+2.68 (+57.63%)
since 05/16/18
52-Week
2.78 +163.67%
on 02/01/18
9.02 -18.74%
on 06/20/18
+3.34 (+83.71%)
since 08/16/17

Most Recent Stories

More News
Quotient (QTNT) Reports Q1 Loss, Tops Revenue Estimates

Quotient (QTNT) delivered earnings and revenue surprises of -48.65% and 14.25%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

QTNT : 7.33 (+1.66%)
Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results

-- $48.8 million of proceeds from warrant exercises received through July 31

QTNT : 7.33 (+1.66%)
Quotient Limited Announces Details of Investor Day

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today.

QTNT : 7.33 (+1.66%)
Quotient Limited Announces Completion of Senior Secured Notes Offering

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023...

QTNT : 7.33 (+1.66%)
Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks

Stock Research Monitor: QTNT, ADMP, and PETS

PETS : 36.79 (-0.27%)
ADMP : 2.83 (-16.91%)
QTNT : 7.33 (+1.66%)
Quotient Limited to Host Investor Day on July 16, 2018

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am - 1:00pm ET, in New York, NY. At the event,...

QTNT : 7.33 (+1.66%)
Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

-- Field trial concordance data exceed targeted criteria

QTNT : 7.33 (+1.66%)
Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, will be released before...

QTNT : 7.33 (+1.66%)
Quotient Limited Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts

Quotient Limited ("Quotient") (NASDAQ: QTNT), an established, commercial-stage diagnostics company, today announced the recent FDA approval for U.S. commercialization of seven new blood bank reagents including...

QTNT : 7.33 (+1.66%)
Pre-Market Technical Scan on Healthcare Equities -- Atossa Genetics, Palatin Technologies, Quotient, and Avadel Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ATOS, PTN, QTNT, and AVDL which can be accessed for free by signing up to www.wallstequities.com/registration....

AVDL : 4.77 (-2.45%)
ATOS : 2.31 (+6.45%)
PTN : 0.97 (+3.74%)
QTNT : 7.33 (+1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade QTNT with:

Business Summary

Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania....

See More

Key Turning Points

2nd Resistance Point 7.64
1st Resistance Point 7.49
Last Price 7.33
1st Support Level 7.15
2nd Support Level 6.97

See More

52-Week High 9.02
Last Price 7.33
Fibonacci 61.8% 6.64
Fibonacci 50% 5.90
Fibonacci 38.2% 5.16
52-Week Low 2.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar